Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19648343 | 1.00 | MMP1 (0.35) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL16664444 | 1.00 | MMP1 (0.35) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL17055731 | 1.00 | MMP1 (0.35) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL19541987 | 0.85 | EPHX2 (0.41) | MMP1MMP9MMP14MMP2EPHX2 | |
| SCHEMBL23011460 | 0.84 | MMP1 (0.42) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL18885414 | 0.80 | EPHX1 (0.35) | EPHX2ALDH1A1 | |
| SCHEMBL18885416 | 0.80 | EPHX1 (0.35) | EPHX2ALDH1A1 | |
| SCHEMBL6392066 | 0.79 | MMP1 (0.42) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL31547122 | 0.79 | MMP1 (0.42) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL19009035 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847198-B1 | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR-GAMMA AND THE TREATMENT OF DISEASE | LYCERA CORP (US) | 2016-12-14 | — | — | EP | disclosed |